[1] |
McGrath EE, Anderson PB. Increased prevalence of non-tuberculous mycobacteria infection. Lancet, 2007,370(9581):28. doi: 10.1016/S0140-6736(07)61044-7.
|
[2] |
Jing H, Wang H, Wang Y, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004—2009. Emerg Infect Dis, 2012,18(3):527-528. doi: 10.3201/eid1803.110175.
|
[3] |
Hernández-Garduño E, Elwood RK. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000—2008. Emerg Infect Dis, 2010,16(6):1047-1048. doi: 10.3201/eid1606.100228.
|
[4] |
Lee MR, Sheng WH, Hung CC, et al. Mycobacterium abscessus Complex Infections in Humans. Emerg Infect Dis, 2015,21(9):1638-1646. doi: 10.3201/2109.141634.
|
[5] |
Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol, 2009,107(2):356-367. doi: 10.1111/j.1365-2672.2009.04161.x.
|
[6] |
Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet, 2013,381(9877):1551-1560. doi: 10.1016/S0140-6736(13)60632-7.
|
[7] |
Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016,354(6313):751-757. doi: 10.1126/science.aaf8156.
|
[8] |
Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med, 2009,180(9):896-902. doi: 10.1164/rccm.200905-0704OC.
|
[9] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007,175(4):367-416. doi: 10.1164/rccm.200604-571ST.
|
[10] |
Li X, Hernandez V, Rock FL, et al. Discovery of a Potent and Specific M.tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem, 2017,60(19):8011-8026. doi: 10.1021/acs.jmedchem.7b00631.
|
[11] |
Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science, 2007,316(5832):1759-1761. doi: 10.1126/science.1142189.
|
[12] |
Dong W, Li S, Wen S, et al. In Vitro Susceptibility Testing of GSK656 against Mycobacterium Species. Antimicrob Agents Chemother, 2020,64(2):e01577-19. doi: 10.1128/AAC.01577-19.
|
[13] |
Zhang Z, Pang Y, Wang Y, et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Agents, 2015,45(5):491-495. doi: 10.1016/j.ijantimicag.2015.01.012.
|
[14] |
赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 75-87.
|
[15] |
Shen Y, Wang X, Jin J, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int, 2018,2018:4902941. doi: 10.1155/2018/4902941.
|
[16] |
Zhang Z, Lu J, Liu M, et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. Int J Antimicrob Agents, 2017,49(3):383-386. doi: 10.1016/j.ijantimicag.2016.12.003.
|
[17] |
Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother, 2012,67(4):810-818. doi: 10.1093/jac/dkr578.
|
[18] |
Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis, 2017,64(3):309-316. doi: 10.1093/cid/ciw724.
|
[19] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020,43(11):918-946. doi: 10.3760/cma.j.cn112147-20200508-00570.
|
[20] |
张智健. 脓肿分枝杆菌复合群的药物敏感性分析及其对克拉霉素的耐药机制研究. 北京:中国人民解放军总医院解放军医学院, 2015: 1-222.
|
[21] |
Jesus FP, Ferreiro L, Loreto ÉS, et al. In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. Antimicrob Agents Chemother, 2014,58(9):5621-5625. doi: 10.1128/AAC.02349-14.
|
[22] |
Mukherjee D, Wu ML, Teo JWP, et al. Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro. Antimicrob Agents Chemother, 2017,61(12):e01298-17. doi: 10.1128/AAC.01298-17.
|